NCT05366478View on ClinicalTrials.gov

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

May 30, 2024

Study Completion Date

May 30, 2029

Conditions
MelanomaNon Small Cell Lung CancerCervical Carcinoma
Interventions
DRUG

Autologous tumor infiltrating lymphocytes (TILs)

A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients will be infused with LM103 Injection followed by IL-2.

Trial Locations (1)

300000

RECRUITING

Tianjin Beichen Hospital, Tianjin

All Listed Sponsors
lead

Suzhou BlueHorse Therapeutics Co., Ltd.

INDUSTRY